Articles tagged "Rejection"

2017 American Transplant Congress
A Molecular Signature Characterized by Dominance of Negative Regulation over Cytotoxic Effectors in Tolerant Kidney Allograft Recipients.
J. Lee,¹ J. Leventhal,² C. Li,¹ A. Katapodis,³ S. Ildstad,⁴ M. Suthanthiran.¹
¹Medicine, Weill Cornell, NY, NY; ²Surgery, Northwestern Medicine, Chicago, IL; ³Novartis, Basel, Switzerland; ⁴Regenerex, Louisville, KY
Introduction. Development of tolerance biomarkers is important for interrogating the in-vivo immune status of patients entered in clinical trials of tolerance.Methods. To determine the feasibility…
2017 American Transplant Congress
Meta-Analysis of Clinical Significance of Complement Activating Anti-HLA DSA in Kidney Transplantation.
A. Bouquegneau,^1,2 C. Ulloa,¹ O. Aubert,¹ C. Loheac,¹ D. Viglietti,¹ J. Empana,¹ P. Jabre,¹ X. Jouven,¹ C. Lefaucheur,¹ A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²Department of Nephrology, Dialysis and Transplantation, Liège, Belgium
Donor-specific anti-HLA antibodies (DSA) are currently recognized as the major limitation to access transplantation and the first cause of late transplant failures. The effect of…
2017 American Transplant Congress
Similar Elevation of Gene Expression Associated with Antibody-Mediated Rejection (ABMR) of Renal Allografts Can Be Detected in Both Plasma Exosomes (pExo) and Biopsies (Bx) by Assessing mRNA Transcript Profiles.
H. Zhang,¹ C. Nast,² J. Doldron,² M. Cheung,² J. Mirocha,³ J. Kahwaji,¹ A. Vo,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles; ²Pathology, Cedars-Sinai Medical Center, Los Angeles; ³Biostatistics Center, Cedars-Sinai Medical Center, Los Angeles
Background: ABMR is a major obstacle for successful transplant in HLA-sensitized patients (Pts). Prediction of ABMR by non-invasive diagnostic tools is desirable. Previously we showed…
2017 American Transplant Congress
Risk Factors of Treatment Failure in Antibody Mediated Rejection.
V. Pernin,¹ I. Szwarc,¹ T. Kanouni,² V. Garrigue,¹ J. Serre,¹ S. Delmas,¹ G. Mourad,¹ M. Le Quintrec.¹
¹Department of Nephrology, Dialysis and Transplantation, CHU Lapeyronie, Montpellier, France; ²Department of Hematology, CHU St ELoi, Montpellier, France
Background: Antibody-mediated rejection (AMR) is recognized as the major cause of kidney allograft loss. Despite an aggressive treatment, prognosis is usually poor. The aim of…
2017 American Transplant Congress
The Role of Toll-Like Receptor 4 in Islet Transplantation and a Novel Method of Protection Using Chemical Surface Modification.
C. Chang,¹ G. Yoshimatsu,² B. Akinbobuyi,⁴ M. Lawrence,² R. Kane,¹ B. Naziruddin.³
¹Institute of Biomedical Studies, Baylor University, Waco, TX; ²Baylor Scott and White Research Institute, Dallas, TX; ³Baylor Simmons Transplant Institute, Dallas, TX; ⁴Department of Chemistry and Biochemistry, Baylor University, Waco, TX
Toll-like Receptor 4 (TLR4) is the canonical receptor for lipopolysaccharide (LPS), however recent evidence reveals that TLR4 also plays an important role in ischemia-reperfusion injury…
2017 American Transplant Congress
Inhibition of Bruton Tyrosine Kinase Blocks Sensitization in Response to Allogeneic Skin Transplantation and Prolong Skin Graft Survival.
N. Datta, T. Palumbo, J. Kupiec-Weglinski, A. Zarrinpar.
Surgery, University of California, Los Angeles, CA
Antibody mediated rejection and donor specific antibodies are important causes of both early (hyperacute) and late (chronic) graft loss. Bruton tyrosine kinase (Btk) is required…
2017 American Transplant Congress
Characterization of De Novo Donor-Specific HLA Antibodies and Correlations with C4d+ Antibody-Mediated Rejection of Kidney Transplants.
R. Rajalingam,¹ D. Kopchaliiska,¹ O. Buenaventura,¹ M. Singh,² S. Tomlanovich.²
¹Immunogenetics and Transplantation Laboratory, Depart. of Surgery, University of California San Francisco, San Francisco, CA; ²Transplant Service, Department of Medicine, University of California San Francisc, San Francisco, CA
Aim: Characteristics of de novo donor-specific HLA antibodies (dnDSA) that are associated with C4d positive antibody-mediated rejection (C4d+ AMR) in kidney transplants have not been…
2017 American Transplant Congress
Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients.
P. Zhang,¹ H. Amer,² C. Schinstock,² M. Alexander,¹ F. Cosio,² M. Stegall,³ L. Cornell.¹
¹Anatomic Pathology, Mayo Clinic, Rochester; ²Nephrology, Mayo Clinic, Rochester; ³Transplant Surgery, Mayo Clinic, Rochester
Background: Alemtuzumab induction (AZI) can be used for early steroid withdrawal in kidney transplant (KTx) recipients. There is evidence that AZI-induced lymphocyte depletion leads to…
2017 American Transplant Congress
Does Gender Affect Renal Transplant Outcomes?
A. Patel, R. Prashar.
Department of Internal Medicine, Division of Nephrology, Henry Ford Transplant Institute, Detroit, MI
Many studies have evaluated the role of gender on renal transplantation.Females (F) are less likely than males (M) to be on the waitlist (WL); less…
2017 American Transplant Congress
Preventing Alloimmune Rejection in Heart Transplantation by Tolerogenic Dendritic Cells Induced by GDF15 Through Up-Regulation of IDO and Inhibition of the NFκB Signalling Pathway.
Y. Zhang,^1,3 G. Zhang,¹ L. Moszczynski,¹ D. Zhao,^1,3 P. Abulizi,¹ D. Quan,² T. Mele,² K. Liu,³ X. Zheng.^1,2
¹Pathology, University of Western Ontario, London, ON, Canada; ²Surgery, University of Western Ontario, London, ON, Canada; ³Cardiovascular Surgery, Jilin University, Cahngchun, China
Rationale: Growth differentiation factor 15 (GDF15) can inhibit DC maturation, yet whether it can generate tolerogenic dendritic cells (Tol-DCs) to induce immune tolerance in heart…